Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by snuff133on Mar 16, 2021 9:35am
232 Views
Post# 32806485

RE:VENTRIPOINT JV BEGINS PROCESS TO HAVE HEART ANALYSIS SYSTEM

RE:VENTRIPOINT JV BEGINS PROCESS TO HAVE HEART ANALYSIS SYSTEM Dear Friend;

Attached is a press release outlining progress in China where our JV partner Yutian is reporting a new initiative by the Chinese government to equip all ICUs with a way to evaluate the right ventricle (RV) of the heart.  

Here is some background:

1.    Studies have shown 40% of COVID patents have dilated RVs, which is the first stage of chronic RV failure and needs to be treated immediately.  RV size is correlated to death (the more the dilation the more likely the patient will die).
2.    China has clearly crunched the data and seen the need for RV assessment to properly treat and triage COVID patients in an ICU based upon RV dilation and so has made this a mandate for ICUs.  I can only hope hospitals world-wide follow their lead.
3.    The RV is a thin weak muscle as it does not usually take much effort to pump blood through the lungs and so it does not take much lung congestion to over-stress the RV.  It also has very little capacity to recover form stress (unlike the LV which recovers even after many years of stress once the stress is removed).
4.    The QAS (VMS name in China) is ideal to meet the need to assess the RV and this would increase the market in China significantly as now hospitals would need QAS machines in their echocardiography departments for routine use as well as their ICUs for COVID patients.
5.    Cardiac ultrasound is done much more frequently in ChIna then elsewhere in the world as every patient going for any type of surgery must have an echocardiogram done and so the echocardiography units at Chinese hospitals are very large and will require many QAS machines per hospital to deal with patient flow.
6.    I am not certain how long the process will be in China to have the QAS certified for use in COVID patients.  I imagine if there is a flare up of COVID cases, it would happen very quickly.  I know everyone is concerned about variants that are more infectious and lethal.
7.    Kings College in London is using their VMS+3.0 on COVID patents and we are executing a PO from a second COVID centre in the UK any day now.  The UK has announced plans to establish 40 COVID-specific clinics to deal with long-COVID patients and these patients would require multiple echocardiograms over the next year.
8.    We are also expecting a PO from a major centre in the USA, which has been active in publishing on the need for RV assessment in COVID patents.

Thank you for your continued support and interest as we continue on our mission to improve cardiac care for everyone world-wide and especially for children..
<< Previous
Bullboard Posts
Next >>